Evidence
iScience. 2024 Jan 4;27(2):108783. doi: 10.1016/j.isci.2024.108783. eCollection 2024 Feb 16.
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD), which has a prevalence of over 25% in adults, encompasses a wide spectrum of liver diseases. Metabolic-dysfunction associated steatotic liver disease (MASLD), the new term for NAFLD, is characterized by steatotic liver disease accompanied by cardiometabolic criteria, showing a strong correlation with metabolic diseases. Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disease affecting 4-21% of women of reproductive age. Numerous studies have indicated that NAFLD and PCOS often occur together. However, as MASLD is a new term, there is still a lack of reports describing the effects of MASLD on the development of PCOS. In this review article, we have summarized the complex and multifaceted connections between MASLD and PCOS. Understanding the pathogenesis and treatment methods could not only guide the clinical prevention, diagnosis, and treatment of PCOS in patients with MASLD, but also increase the clinical attention of reproductive doctors to MASLD.
PMID:38292434 | PMC:PMC10825666 | DOI:10.1016/j.isci.2024.108783
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
🌐 90 Days
VR Related Evidence Matrix
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- The double roles of T cell-mediated immune response in the progression of MASLD
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- New nomenclature for fatty liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study
- Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study
- Spatial genomics: mapping human steatotic liver disease
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
- Role of the angiopoietin-like protein family in the progression of NAFLD
- COVID-19 in Individuals with Chronic Liver Diseases
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- Electrocardiographic Abnormalities in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
- Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease: A cross-sectional study of NHANES 2017-2018
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Epigenetic/circadian clocks and PCOS
- Anxiety and depression in metabolic-associated steatotic liver disease: relation with socio-demographic features and liver disease severity
- TET3 boosts hepatocyte autophagy and impairs non-alcoholic fatty liver disease by increasing ENPP1 promoter hypomethylation
- Gestational diabetes mellitus may predispose to metabolic dysfunction-associated steatotic liver disease
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort
- COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS
- Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action
- Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Long-term risk of cardiovascular disease associated with MASLD and different cardiometabolic risk factors in IBD patients: A prospective cohort study
- Metabolic dysfunction-associated fatty liver disease and low muscle strength: A comment
- The gut-liver axis in fatty liver disease: role played by natural products
- The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review
- Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting
- Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome
- Inflammatory liver diseases and susceptibility to sepsis
- Association between endocrine-disrupting chemical mixtures and non-alcoholic fatty liver disease with metabolic syndrome as a mediator among adults: A population-based study in Korea
- Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study
- Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
- Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies
- Non-alcoholic Fatty Liver Disease Among Iraqi Patients With Psoriasis: A Case-Control Study
- Non-alcoholic Fatty Liver Disease Among Iraqi Patients With Psoriasis: A Case-Control Study
- Imbalance of mitochondrial fusion in peripheral blood mononuclear cells is associated with liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis
Evidence Blueprint
Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
🌐 365 Days
VR Related Evidence Matrix
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease
- Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
- Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
- Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease
- Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
- Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
- The Global Epidemic of Metabolic Fatty Liver Disease
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- The double roles of T cell-mediated immune response in the progression of MASLD
- Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- New nomenclature for fatty liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
- Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study
- Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study
- Spatial genomics: mapping human steatotic liver disease
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- Dietary pattern in women with polycystic ovary syndrome with and without associated non-alcoholic fatty liver disease: A cross-sectional study
- Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with non-alcoholic fatty liver disease (NAFLD)
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Polycystic ovary syndrome as a gender-specific cardiometabolic risk factor
- Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Potential Mechanisms Involving in the Pathogenesis of MASLD and Targets for Pharmacotherapy. Advancements in Metabolic Associated Steatotic Liver Disease (MASLD) Research: Diagnostics, Small Molecule Developments and Future Directions
- Relationship between non-alcoholic fatty liver disease and hyperandrogenemia in adolescent with polycystic ovary syndrome
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Metabolic role of hepassocin in polycystic ovary syndrome
- Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
- Metabolic Muddle. MASLD and MASH on the Horizon
- MELD-Na score may underestimate disease severity and risk of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
- From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
- National prevalence estimates for steatotic liver disease and Sub-Classifications using consensus nomenclature
- Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance
- Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the…
- Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Fatty liver disease's renaming impacts on drug clinical trials
- Role of the angiopoietin-like protein family in the progression of NAFLD
- COVID-19 in Individuals with Chronic Liver Diseases